The companies also committed to a co-marketing agreement for future promotion of
Schering-Plough's cardiovascular product, Zetia, in Japan. In addition, Bayer HealthCare will
build up a new U.S.-based global oncology business unit and refocus its U.S. organization on
high-profit specialty and biotech products to form Bayer HealthCare's Specialty Pharmaceuticals
business.
Bayer estimates that approximately 1,800 U.S.-based Bayer primary care sales and marketing
positions will be impacted, either through transfer to Schering-Plough or through staff
reductions.
Bayer's drug products will remain the property and legal responsibility of Bayer and continue to
be sold under the Bayer brand names. The agreement covers only those Bayer products already
approved, not those in development.